Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,733.50
Bid: 1,732.50
Ask: 1,733.00
Change: 5.00 (0.29%)
Spread: 0.50 (0.029%)
Open: 1,733.00
High: 1,739.50
Low: 1,724.50
Prev. Close: 1,728.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TOP NEWS SUMMARY: UK Records First July Budget Surplus Since 2012

Fri, 21st Aug 2015 10:15

LONDON (Alliance News) - The following is a summary of top news stories Friday.
----------
COMPANIES
----------
GlaxoSmithKline said it has signed an agreement with a subsidiary of Swiss peer Novartis to sell its rights to ofatumumab for auto-immune indications, including multiple sclerosis. Under the terms of Glaxo's divestment, it will get USD300 million upon closing of the transaction, USD200 million once a phase 3 study starts into using ofatumumab for relapsing remitting multiple sclerosis, plus further contingent payments of up to USD534 million, payable upon other development milestones being reached. Novartis Pharma will also pay Glaxo royalties of up to 12% on any future net sales of ofatumumab in auto-immune indications.
----------
Zurich Insurance has brought in Evercore Partners to work on a bid for insurer RSA Insurance Group alongside Morgan Stanley, according to a Financial Times report. The newspaper, which cited people with knowledge of the situation, said that investment bank advisers for the two sides remain "far apart" on price. Takeover rules require Zurich to state whether it wants to make a firm offer or walk away by 1700 BST Tuesday next week, according to stock exchange documents.
----------
Spire Healthcare Group cut its revenue guidance for 2015 due to short-term challenges it expects to face in National Health Service activity in the second half, as it reported a rise in pretax profit and revenue for the first half. Spire now expects flat revenue in the second half of 2015, compared to previous guidance of low single-digit growth, due to a slowdown in the flow of cases from the NHS to the independent sector in recent weeks. The cut to the revenue guidance means the group now expects its revenue and earnings before interest, taxation, depreciation and amortisation growth to be 4% to 6% for the full year.
----------
3i Infrastructure said it is taking a 50% holdings in the West of Duddon Sands Offshore Transmission Owner from Dong Energy and Scottish Power Renewables, with the remaining equity in the project to be acquired by Macquarie Capital. 3i Infrastructure is investing GBP23 million in the project.
----------
HellermannTyton Group said its pretax profit and revenue both increased in the first half, buoyed both by a strong performance in the majority of its markets and by the effect of the weak euro, the currency in which it reports. The company, which makes wires and cables and which recently agreed to be acquired by UK-based automotive parts manufacturer Delphi Automotive for GBP1.07 billion, said its pretax profit for the six months to the end of June was EUR42.5 million, up from EUR34.6 million a year earlier. The company said it will pay an interim dividend of 3.09 euro cents per share, up from 2.82 cents a year earlier.
----------
MARKETS
----------
Stocks in London have recovered slightly from their heavy fall at the open, but still trade deeply in the red with disappointing Chinese manufacturing data offsetting subsequent upbeat purchasing managers' index readings from Europe.
----------
FTSE 100: down 0.5% at 6,336.26
FTSE 250: down 0.5% at 17,158.55
AIM ALL-SHARE: down 1.0% at 736.29
----------
GBP: flat at USD1.5687
EUR: up at USD1.1260

GOLD: down at USD1149.48 per ounce
OIL (Brent): up at USD46.29 a barrel

(changes since end of previous GMT day)
----------
ECONOMICS AND GENERAL
----------
The UK logged its first July budget surplus since 2012, the Office for National Statistics showed. Public sector net borrowing excluding public sector banks decreased by GBP1.4 billion to a surplus of GBP1.3 billion or equivalent to -0.1% of gross domestic product in July. This was the first reported July surplus since 2012. Economists had forecast a surplus of GBP1.1 billion.
----------
The manufacturing sector in China continued to struggle in August as the contraction accelerated, a preliminary survey from Caixin showed, with a Performance of Manufacturing Index score of 47.1. That's down from 47.8 in July, and it represents a 77-month low. It also moves further beneath the line of 50 that separates expansion from contraction. "The Caixin Flash China General Manufacturing PMI for August has fallen further from July's two-year low, indicating that the economy is still in the process of bottoming out. But overall, the likelihood of a systemic risk remains under control and the structure of the economy is still improving," said He Fan, chief economist at Caixin Insight Group.
----------
Some 25 hard-left Syriza lawmakers want to break away from the ruling party and form their own parliamentary faction ahead of snap elections on September 20, Greek media reported. The rebels, who refused party leader Alexis Tsipras their support in a vote on further austerity and reforms last week, will call their party National Unity (LAE). It will be the third-largest bloc in parliament after Syriza, which has 124 members, and the conservative Greek opposition party New Democracy (ND), with 76. Tsipras resigned as Greek prime minister on Thursday, hours after the debt-stricken country received the first payment from its third bailout in five years. He said he needed a strong mandate going into talks about further reforms to the Greek economy.
----------
The head of the conservative Greek opposition party Nea Dimokratia will have a chance to form a new government following the surprise resignation of Tsipras, according to an email from the president's office. According to the Greek constitution, the head of the next-largest party gets a chance to form a government after the sitting premier resigns. However, observers say it is unlikely that ND head Evangelos Meimarakis will be able to pull together a government, which would leave Greece on track for its second round of elections this year. Meimarkis is expected to meet with President Prokopis Pavlopoulos around midday to discuss the options after the president's office sent him an email early Friday giving him the mandate to form a new government.
----------
British households perceive that the value of their home increased in August, a survey from Knight Frank and Markit Economic showed. The house price sentiment index rose to 59.5 in August from 58.6 in the previous month. This marked the twenty-ninth successive month of the index remaining above 50. A reading above 50 signals a rise in house prices, while a figure below 50 indicates a decline. "The strength of the UK economy, rising wages and an undersupply of housing stock on the market are combining to underpin UK house prices. This has resulted in the first rise in the House Price Sentiment Index in August, usually a quieter summer period, seen since 2009, " Grainne Gilmore, head of UK residential research at Knight Frank, said.
----------

Eurozone private sector activity growth improved in August largely reflecting an acceleration in Germany, preliminary data from Markit Economics showed. At 54.1, the flash Purchasing Managers' Index ticked higher from July's final reading of 53.9 and remained at an expansionary level for the twenty-sixth successive month. The pace of increase was one of the fastest seen over the past four years and stayed above the expected level of 53.7.

----------
Germany's consumer sentiment is set to drop in September, survey data from market research group GfK showed. The consumer sentiment index fell to 9.9 in September from 10.1 points in August. Economists had forecast it to remain unchanged at 10.1. The economy and income expectations as well as the willingness to buy have suffered losses. The downward trend in economic expectations continued in August. The economic expectations index dropped 1.8 points to 16.6.
----------
By Arvind Bhunjun; arvindbhunjun@alliancenews.com; @ArvindBhunjun

Copyright 2015 Alliance News Limited. All Rights Reserved.

More News
3 Apr 2024 21:37

What to know about bird flu in dairy cows and the risk to humans

CHICAGO, April 3 (Reuters) - Texas officials reported on Monday that a farm worker tested positive for H5N1, or bird flu, that has spread to dairy cows in Texas, Kansas, New Mexico, Michigan and Idaho - the first time the virus has infected cattle.

Read more
19 Mar 2024 09:21

LONDON BROKER RATINGS: Investec cuts ConvaTec; RBC raises Vistry

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
18 Mar 2024 12:00

GSK unveils promising results from endometrial cancer trial

(Sharecast News) - GSK unveiled promising outcomes from a phase three trial of 'Jemperli', or dostarlimab, in treating primary advanced or recurrent endometrial cancer on Monday.

Read more
18 Mar 2024 08:47

TOP NEWS: Pfizer launches GBP2 billion sale of 8% stake in Haleon

(Alliance News) - Haleon PLC on Monday said Pfizer Inc plans to sell around GBP2 billion in Haleon shares, some of which will be bought back by Haleon.

Read more
18 Mar 2024 08:47

GSK says Jemperli combination gets good results for endometrial cancer

(Alliance News) - GSK PLC on Monday said a test of its Jemperli drug in combination with chemotherapy has shown it reduced the risk of death in patients with endometrial cancer by nearly a third.

Read more
7 Mar 2024 09:38

GSK observes positive data in Blenrep trial for blood cancer treatment

(Alliance News) - GSK PLC on Thursday announced positive results for Blenrep for the treatment of multiple myeloma.

Read more
7 Mar 2024 07:21

GSK reports more encouraging trial results for Blenrep

(Sharecast News) - GSK unveiled encouraging results from its 'DREAMM-8' phase three trial on Thursday, comparing the efficacy of 'Blenrep', or belantamab mafodotin, in combination with pomalidomide plus dexamethasone, or PomDex, against the standard treatment of bortezomib plus PomDex in relapsed or refractory multiple myeloma patients.

Read more
5 Mar 2024 11:03

GSK says ViiV's cabotegravir study supports longer HIV dose interval

(Alliance News) - GSK PLC on Tuesday celebrated study results from ViiV Healthcare Ltd, that showed an investigational formulation of cabotegravir can be dosed at four-month intervals.

Read more
5 Mar 2024 07:26

GSK's ViiV upbeat on ultra-long-acting HIV treatment study

(Sharecast News) - GSK announced on Tuesday that its specialist GIV joint venture with Pfizer and Shionogi, ViiV Healthcare, had reported encouraging results from its phase one clinical trial of an investigational formulation of cabotegravir, termed cabotegravir ultra long-acting (CAB-ULA).

Read more
29 Feb 2024 09:44

TOP NEWS: GSK avoids "protracted litigation" with Zantac settlement

(Alliance News) - GSK PLC on Thursday emphasised its commitment to science, as it reached another settlement in ongoing litigation over alleged links between its heartburn drug and cancer.

Read more
29 Feb 2024 07:22

GSK reaches settlement in another Zantac case

(Sharecast News) - GSK announced a confidential settlement with Boyd/Steenvoord, effectively resolving a case filed in California state court over its discontinued heartburn drug Zantac.

Read more
26 Feb 2024 08:25

GSK gonorrhoea treatment achieves efficacy endpoint in latest trial

(Alliance News) - GSK PLC on Monday announced positive results from the latest trial of its oral gonorrhoea treatment, showing it to be on par with intramuscular therapies.

Read more
26 Feb 2024 07:22

GSK reports positive results from gonorrhoea treatment trial

(Sharecast News) - GSK announced encouraging headline outcomes from its trial of gepotidacin, an oral antibiotic aiming to address uncomplicated urogenital gonorrhoea in adolescents and adults, on Monday.

Read more
21 Feb 2024 09:47

GSK reports encouraging results for ViiV's Cabenuva HIV treatment

(Alliance News) - GSK PLC on Wednesday said that its majority-owned company ViiV Healthcare had received positive interim data from ongoing trials of its injectable HIV treatment.

Read more
21 Feb 2024 07:22

GSK's ViiV sees success in latest HIV treatment trial

(Sharecast News) - GSK's specialist HIV unit ViiV Healthcare, which it owns in partnership with Pfizer and Shionogi, unveiled promising findings from the 'LATITUDE' phase three trial of its long-acting injectable HIV treatment Cabenuva on Wednesday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.